Medline (NASDAQ:MDLN) Coverage Initiated by Analysts at Citigroup

Equities researchers at Citigroup began coverage on shares of Medline (NASDAQ:MDLN) in a research note issued to investors on Monday. The brokerage set a “buy” rating and a $48.00 price target on the stock. Citigroup’s price target would suggest a potential upside of 14.18% from the company’s current price.

Several other brokerages have also recently issued reports on MDLN. Sanford C. Bernstein began coverage on Medline in a research report on Monday. They set an “outperform” rating and a $49.00 target price on the stock. Evercore ISI assumed coverage on shares of Medline in a report on Monday. They set an “outperform” rating and a $50.00 price objective on the stock. Piper Sandler started coverage on shares of Medline in a report on Monday. They issued an “overweight” rating and a $50.00 target price for the company. Rothschild & Co Redburn initiated coverage on shares of Medline in a report on Monday. They set a “neutral” rating and a $42.00 price target on the stock. Finally, Barclays began coverage on shares of Medline in a research report on Monday. They issued an “overweight” rating and a $50.00 price objective for the company. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Medline presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.58.

Medline Stock Performance

Shares of MDLN traded up $1.52 on Monday, reaching $42.04. The company’s stock had a trading volume of 1,164,562 shares, compared to its average volume of 5,571,718. Medline has a twelve month low of $34.89 and a twelve month high of $45.50.

Insiders Place Their Bets

In other news, Director Charles N. Mills acquired 2,579,310 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $29.00 per share, for a total transaction of $74,799,990.00. Following the completion of the transaction, the director owned 2,441,379 shares of the company’s stock, valued at $70,799,991. The trade was a -1,870.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the sale, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. This trade represents a 55.88% decrease in their position. The disclosure for this sale is available in the SEC filing.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies initiated coverage with a Buy and $50 target, highlighting Medline’s scale (a cited $25B supply‑chain advantage) as a key driver for margin and growth upside. Read More.
• Positive Sentiment: Barclays started coverage Overweight with a $50 target, joining other major shops that see meaningful upside tied to Medline’s distribution scale. Read More.
• Positive Sentiment: Wolfe Research (Outperform, $47), Mizuho (Outperform, $48) and JPMorgan (Overweight, $50) all initiated positive ratings, reinforcing a consensus bullish view on share gains from market share and margin expansion. Read More. Read More.
• Positive Sentiment: Multiple boutique and sector analysts (Bernstein, Baird, Piper Sandler, Truist, Stifel, William Blair, Leerink and others) also initiated Buy/Overweight calls, citing the “prime‑vendor” model, branded mix shift and visible margin runway; see a TipRanks roundup of these initiations. Read More.
• Positive Sentiment: Positive media/TV coverage (including Jim Cramer commentary) has added to the bullish tone, amplifying retail and institutional interest. Read More.
• Neutral Sentiment: Wells Fargo initiated with an Equal Weight and $42 target, and Rothschild/Redburn started Neutral at $42 — signaling some caution on near‑term upside despite the broader buy consensus. Read More.
• Negative Sentiment: Deutsche Bank started with a Hold and $40 target (slight downside vs. current levels), representing the most cautious early call and a reminder of valuation risk if execution or margins disappoint. Read More.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.